Anagram Therapeutics vs Epicrispr Biotechnologies
Anagram Therapeutics vs Epicrispr Biotechnologies, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Anagram Therapeutics is on 55/100 and Epicrispr Biotechnologies on 62/100.
Where each one leads
Anagram Therapeutics
- agent readiness: 44/100 against 39/100
- funding raised: $285M against $90.0M
Epicrispr Biotechnologies
- our overall score: 62/100 against 55/100
- domain rating: 40/100 against 16/100
At a glance
| Measure | Anagram Therapeutics | Epicrispr Biotechnologies |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency. | Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD). |
| Category | Biotechnology, Pharmaceuticals, Healthcare, Biotech | Biotechnology, Therapeutics, Rare Diseases, Epigenetics |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Services | Platform |
| Founded | 2017 | 2020 |
| Headquarters | Natick, USA | South San Francisco, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Anagram Therapeutics | Epicrispr Biotechnologies |
|---|---|---|
| Employees | Not published | 51 |
| Total funding | $285M | $90.0M |
| Latest round | Investment | Series C |
| LinkedIn followers | Not published | 7,025 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Anagram Therapeutics | Epicrispr Biotechnologies |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 55/100 | 62/100 |
| Traction | 40/100 | 57/100 |
| Team | 60/100 | 40/100 |
| Search visibility | 18/100 | 20/100 |
| Quality | 68/100 | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 16/100 | 40/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Anagram Therapeutics | Epicrispr Biotechnologies |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Tailwind CSS, Bootstrap | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Analytics 4 | Google Analytics 4 |
Anagram Therapeutics vs Epicrispr Biotechnologies: common questions
Which is better, Anagram Therapeutics or Epicrispr Biotechnologies?
On our 0-100 score Epicrispr Biotechnologies rates higher (62/100 against 55/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Anagram Therapeutics and Epicrispr Biotechnologies compare on the numbers?
Anagram Therapeutics leads on agent readiness (44/100 against 39/100), funding raised ($285M against $90.0M). Epicrispr Biotechnologies leads on our overall score (62/100 against 55/100), domain rating (40/100 against 16/100).
Read the full Anagram Therapeutics review and pricing or the Epicrispr Biotechnologies review and pricing. You can also browse other Anagram Therapeutics alternatives we track.